AbbVie’s quiet acquisition of Gilgamesh Pharmaceuticals, reportedly worth close to $1 billion, did more than make headlines. It signaled something far more significant: Big Pharma has officially entered the psychedelic-adjacent…
Read More
Psychedelic drugs have been on quite the trip. Though they have been used culturally for thousands of years for medicinal and spiritual reasons—from psilocybin-containing mushrooms in Aztec rituals to the…
Read More
AbbVie’s rumored $1 billion acquisition of Gilgamesh Pharmaceuticals has amplified attention on the psychedelic therapeutics sector. Stocks of companies like Cybin, Mind Medicine, and GH Research have surged, driven by…
Read More
We are now well into what is often called the “psychedelic renaissance,” and the field has made genuine progress alongside all the early excitement. Many groups new to the realities…
Read More
Psychedelic drugs have the potential to become an effective treatment for crippling mental health conditions such as depression. In this article, we take a look at six of the top…
Read More
Richard Zwicky spoke with Dr. Joseph Tucker, CEO of Enveric Biosciences about their development of non-hallucinogenic neuroplastogens, inspired by psychedelic research, to stimulate neuroplasticity for therapeutic benefits. Listen to Podcast…
Read More
In the shadow of headlines about the mental health crisis and the limits of current psychiatric care, one small biotech is making quiet but meaningful progress. Enveric Biosciences (NASDAQ: ENVB)…
Read More
New data confirms Enveric’s lead neuroplastogen acts on a serotonin receptor tied to depression, Parkinson’s, and migraine. Enveric Biosciences has announced that EB-003, its oral, non-hallucinogenic neuroplastogen, also acts as…
Read More
In an industry defined by bold ideas and even bolder challenges, Enveric Biosciences (NASDAQ: ENVB) is quietly making a case to lead the next generation of neuropsychiatric drug innovation. On…
Read More
With U.S. Patent No. 12,187,679 now granted, Enveric Biosciences has secured more than intellectual property—it’s staked a claim on the future of neurotherapeutics. The Cambridge-based biotech firm announced this week…
Read More
